MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Soleno Therapeutics Cost of Revenue 2011-2025 | SLNO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Soleno Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 1.51 M | 353 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 M | 353 K | 931 K |
Quarterly Cost of Revenue Soleno Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.14 M | 696 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42 K | 209 K | - | 399 K | 51 K | 461 K | - | 56 K | 22 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.14 M | 18 K | 310 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 38.85 | 2.32 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 16.36 | -4.05 % | $ 176 M |  China |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 17.05 | -2.15 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
9.67 B | $ 227.08 | -2.28 % | $ 166 B | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 101.58 | 0.21 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 27.13 | 0.26 % | $ 820 M | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.63 | -2.11 % | $ 2.07 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
1.33 B | $ 66.91 | -2.94 % | $ 25.8 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 11.92 | -6.58 % | $ 338 M | Israel |
 |
Illumina
ILMN
|
1.51 B | $ 134.29 | -1.58 % | $ 21.4 B | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 221.54 | -1.96 % | $ 40.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
546 M | $ 66.11 | 4.76 % | $ 4.57 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 20.44 | 3.23 % | $ 1.1 B | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 0.34 | -2.96 % | $ 9.98 M | USA |
 |
Myriad Genetics
MYGN
|
252 M | $ 7.26 | -0.62 % | $ 658 M | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 6.86 | -2.63 % | $ 1.49 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 263.51 | -0.46 % | $ 22.1 B | USA |
 |
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
148 M | $ 2.13 | -1.61 % | $ 540 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 26.6 | -1.52 % | $ 20 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
13.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
20.1 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
RadNet
RDNT
|
1 B | $ 75.0 | -4.65 % | $ 5.48 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 182.21 | 0.35 % | $ 20.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 186.28 | -1.92 % | $ 15.4 B |  Irlanda |